CHAPTER 4 206 HF Registry. Journal of the American Heart Association 2020;9:e012199. doi:10.1161/JAHA.119.012199. 65. Savarese G, Vasko P, Jonsson Å, Edner M, Dahlström U, Lund LH. The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. Upsala Journal of Medical Sciences 2018;0:1–5. doi:10.1080/03009734.2018.1490831. 66. European Commission. Final Report Summary - BIOSTAT-CHF (A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure) | FP7 | CORDIS | European Commission 2016. https://cordis.europa.eu/project/id/242209/reporting (accessed July 4, 2022). 67. Brugts JJ, Linssen GCM, Hoes AW, Brunner-La Rocca HP, CHECK-HF investigators. Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands : Design and rationale of the Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) registry. Neth Heart J 2018;26:272–279. doi:10.1007/s12471-018-1103-7. 68. Joseph A. Franciosa MD. The Potential Role of Community-based Registries to Complement the Limited Applicability of Clinical Trial Results to the Community Setting: Heart Failure as an Example. The American Journal of Managed Care 2004;10. 69. Wolfson M, Wallace SE, Masca N, Rowe G, Sheehan NA, Ferretti V, et al. DataSHIELD: resolving a conflict in contemporary bioscience—performing a pooled analysis of individual-level data without sharing the data. International Journal of Epidemiology 2010;39:1372–1382. doi:10.1093/ije/dyq111. 70. World Economic Forum. Federated data systems: Balancing innovation and trust in the use of sensitive data. Geneva, Switzerland: World Economic Forum; 2019. 71. Dursi LJ, Bozoky Z, de Borja R, Li H, Bujold D, Lipski A, et al. CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis. Cell Genomics 2021;1:100033. doi:10.1016/j.xgen.2021.100033. 72. Schoffer O. Statistik in Sachsen. SAS im Forschungsdatenzentrum der Statistischen Landesämter, Sachsen: 2008, p. 123–126. 73. Sartipy U, Dahlström U, Edner M, Lund LH. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish heart failure registry. Eur J Heart Fail 2014;16:173–179. doi:10.1111/ejhf.32. 74. Cellamare M, van Gestel AJ, Alradhi H, Martin F, Moncada-Torres A. A Federated Generalized Linear Model for Privacy-Preserving Analysis. Algorithms 2022;15:243. doi:10.3390/a15070243. 75. Li W, Tong J, Anjum MdM, Mohammed N, Chen Y, Jiang X. Federated learning algorithms for generalized mixed-effects model (GLMM) on horizontally partitioned data from distributed sources. BMC Medical Informatics and Decision Making 2022;22:269. doi:10.1186/s12911-02202014-1. 76. Eisenstein EL, Lemons PW, Tardiff BE, Schulman KA, Jolly MK, Califf RM. Reducing the costs of phase III cardiovascular clinical trials. Am Heart J 2005;149:482–488. doi:10.1016/j.ahj.2004.04.049. 77. Sertkaya A, Wong H-H, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clinical Trials 2016;13:117–126. doi:10.1177/1740774515625964. 78. Moore TJ, Zhang H, Anderson G, Alexander GC. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018;178:1451–1457. doi:10.1001/jamainternmed.2018.3931. 79. Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, et al. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol 2015;65:1567–1582. doi:10.1016/j.jacc.2015.03.016. 80. Sertkaya A, Birkenbach A, Berlind A, Eyraud J. Examination of Clinical Trial Costs and Barriers for Drug Development. Washington DC: US Department of Health and Human Services; 2014. 81. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther 2010;88:166– 182. doi:10.1038/clpt.2010.114. 82. Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 2005;96:228–234. doi:10.1111/j.1742-7843.2005.pto960313.x.
RkJQdWJsaXNoZXIy MjY0ODMw